
© 2025 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
272,30 | 272,80 | 22:42 | |
272,30 | 273,00 | 22:00 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mi | F. Hoffmann-La Roche Ltd: Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis | The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-expressed in some patients with non-squamous non-small cell lung cancer (NSQ-NSCLC).The MET protein serves... ► Artikel lesen | |
Mi | Genentech pays tribute to moms of children with hemophilia A in Hemlibra short film | ||
Mi | Novartis und Roche kündigen Widerstand gegen Trumps Pläne an | ||
Mi | Roche to reconsider US investment projects if Trump follows through on pricing order | ||
Mi | Roche reportedly warns Trump's executive order can risk its U.S. investments |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | Zealand Pharma-Roche Obesity Drug Deal Now Effective After Satisfying All Conditions | ||
Fr | Zealand Pharma announces closing of collaboration and license agreement with Roche | Company announcement - No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 - Zealand Pharma A/S ("the Company" or "Zealand... ► Artikel lesen | |
08.05. | Zealand Pharma reports Q1 results | ||
08.05. | Zealand Pharma Q1 2025 slides: Roche partnership bolsters cash position amid rising R&D costs | ||
08.05. | Zealand Pharma Announces Financial Results for the First Three Months of 2025 | Company announcement - No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities... ► Artikel lesen |
Unternehmen / Aktien | Kurs | % |
---|---|---|
ROCHE HOLDING AG GS | 272,80 | +1,19 % |
ZEALAND PHARMA A/S | 53,84 | -2,46 % |